Business
Microbix Launches New Products to Support H3N2 Flu Testing
MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OT...
About this update from Microbix Biosystems Inc.
[{"type":"text","content":"Microbix Launches New Products to Support H3N2 Flu TestingTest-Controls & Reference Materials for Labs & Test-Makers\n\n\n\n MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (\n \n TSX: MBX, OTCQX: MBXBF, Microbix\n \n ®\n \n\n ), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of\n \n QAPs™\n \n quality assessment products and availability of\n \n QUANTDx™\n \n reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A (a.k.a., the “\n \n Flu\n \n ”).\n \n\n H3N2, alongside H1N1, is a common type of Influenza A that circulates annually, with H3N2 more prone to “antigenic drift,” changing the surface of the virus and its level of recognition by antibodies. These changes can reduce the level of protection natural immunity and vaccine-induced immunity normally provide. Additionally, antigenic drift may reduce the accuracy of “antigen-test” assays for Flu, which can negatively affect disease management by public health agencies and treatment decisions by healthcare providers.\n \n\n A new variant of H3N2 (subclade K) is emerging as the dominant virus for the 2025/26 Flu season. This has been widely-reported in the media as being linked to an early start to this year’s Flu season in the Northern Hemisphere. Accordingly, laboratories and test developers should ensure that all assays in use can reliably detect H3N2 variants of Influenza A within the current multiplex respiratory panels – whether antigen-based or molecular (\n \n e.g.\n \n , PCR-based). This need can now be met using Microbix SARS‑CoV‑2/Flu A (H3N2)/Flu B/RSV QAPs, available on Copan\n \n ®\n \n FLOQSwabs\n \n ®\n \n . These QAPs provide multi‑year room‑temperature stability and complement the existing Microbix respiratory four-plex formulation containing H1N1 Flu A, together creating a portfolio tailored to the current epidemiological landscape.\n \n\n Specifically, Microbix’s Respiratory QAPs formulated with H3N2 can be used as safe, reliable, and stable mimetics of patient-samples for training of persons administering tests, validation of new testing sites, and verification of instrument/assay performance. Depending on the nature of their ...